Abstract Details
|
Michael Eller, MD
PRESENTER |
No disclosure on file |
| Olga Ciccarelli, MD, PhD, FRCP (UCL Institute of Neurology) | Prof. Ciccarelli has received personal compensation in the range of $0-$499 for serving as a Consultant for Lundebeck. Prof. Ciccarelli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Prof. Ciccarelli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Prof. Ciccarelli has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Merck. Prof. Ciccarelli has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NEUROLOGY Journal. |
| Amy Gelfand, MD (UCSF) | An immediate family member of Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Headache Society. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for AAN. The institution of an immediate family member of Dr. Gelfand has received research support from Hoffman LaRoche. The institution of an immediate family member of Dr. Gelfand has received research support from Vigil Neuroscience. The institution of an immediate family member of Dr. Gelfand has received research support from NIH/NINDS. The institution of Dr. Gelfand has received research support from PCORI. The institution of Dr. Gelfand has received research support from UCSF RAP grant. Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Weill Cornell Neurology Department. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Taiwan Headache Society. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Author with Elsevier. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Speaker with College Board SSD. Dr. Gelfand has received personal compensation in the range of $0-$499 for serving as a Speaker with Kobenhavns Unversitet. An immediate family member of Dr. Gelfand has a non-compensated relationship as a Clinical Trial Steering Committee Member with Roche/Genentech that is relevant to AAN interests or activities. |
| Nina Y. Riggins, MD, FAAN (Headache Center of Excellence) | Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG Gerson Lehrman Group . Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amneal Pharmaceuticals. Dr. Riggins has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for NeurologyLive. The institution of Dr. Riggins has received research support from ElectroCore (GammaCore). The institution of Dr. Riggins has received research support from Miles for Migraine. The institution of Dr. Riggins has received research support from Eli Lilly. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has received publishing royalties from a publication relating to health care. Dr. Riggins has a non-compensated relationship as a PI on research study with TheraSpecs that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a Advisory Board with NeurologyLive that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a Member of the Board with Miles for Migraine that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a PI in the study which used sphenocath device with Dolor Technologies that is relevant to AAN interests or activities. Dr. Riggins has a non-compensated relationship as a PI with Theranica that is relevant to AAN interests or activities. |
| Christoph J. Schankin, MD (Department of Neurology, Inselspital, Bern University Hospital) | The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lilly. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lilly. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lundbeck. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Teva. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Grünenthal. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lilly. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. The institution of Dr. Schankin has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Teva. The institution of Dr. Schankin has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Lundbeck. Dr. Schankin has stock in Zynnon. |
| Peter Goadsby, MD, PhD, FRS (King Abdullah Univeristy of Science and Technology) | Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbvie. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teva Pharmaceuticals. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Lundbeck. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Goadsby has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Pfizer. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shiratronics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CoolTech LLC. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Linpharma. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PureTech Health LLC. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Kallyope. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Seaport Therapeutics. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Dr Reddy's. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Orion Pharma. Dr. Goadsby has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Ipsen. Dr. Goadsby has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Massachusetts Medical Society. The institution of Dr. Goadsby has received research support from NIHR. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has received publishing royalties from a publication relating to health care. Dr. Goadsby has a non-compensated relationship as a Trustee with Migraine Trust that is relevant to AAN interests or activities. Dr. Goadsby has a non-compensated relationship as a Trustee with Organisation for Understanding Cluster Headache (UK) that is relevant to AAN interests or activities. |